Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Regeneron Pharma target raised to $446 from $435 at UBS — Raising Dupixent estimates on pricing details (391.92 +9.37)Buy rating reflects optimism on the Dupixent launch, which provides a much needed growth lever as Eylea growth begins to moderate.</td> </tr></table>"